Cantor Fitzgerald Maintains Neutral on Amedisys, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James maintains a Neutral rating on Amedisys (NASDAQ:AMED) and raises the price target from $91 to $100.
June 06, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst raises Amedisys' price target from $91 to $100, maintaining a Neutral rating.
The news of Cantor Fitzgerald raising the price target for Amedisys from $91 to $100 while maintaining a Neutral rating is directly related to the company. However, as the rating remains Neutral, the short-term impact on the stock price is expected to be neutral as well.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100